On April 17, Eli Lilly announced the positive top-line results of the Phase 3 clinical study ACHIEVE-1, which evaluated the safety and efficacy of orforglipron versus placebo in patients with type 2 diabetes whose blood sugar control was still poor on the basis of diet control and exercise. Eli Lilly stated that Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist that successfully completed Phase 3 trials and is not restricted by diet or drinking. Eli Lilly expects to submit an application for orforglipron's use in weight management to global regulators by the end of this year, and expects to submit its application for the treatment of type 2 diabetes in 2026.